


#13158

**REQUEST FOR  
CONTINUED EXAMINATION (RCE)  
TRANSMITTAL**

Subsection (b) of 35 U.S.C. § 132, effective on May 29, 2000, provides for the continued examination of a utility or plant application filed on or after June 8, 1995.



Application Number	09/718,388 8/10/02
Filing Date	November 24, 2000
First Named Inventor	Nobutaka YAMAMOTO et al.
Group Art Unit	1636
Name of Examiner	Konstantina T. Katcheves
Agent Docket No.	001554

This is a Request for Continued Examination (RCE) under 37 C.F.R. § 1.114 of the above-identified application.  
Note: 37 C.F.R. § 1.114 is effective on May 29, 2000. If the above-identified application was filed prior to May 29, 2000, applicant may wish to consider filing a continued prosecution application (CPA) under 37 C.F.R. § 1.53 (PTO/SB/29) instead of a RCE to be eligible for the patent term adjustment provisions of the AIPA. See changes to Application Examination and Provisional Application Practice, Interim Rule, 65 Fed. Reg. 14865 (Mar 20, 2000) 1233 Off. Gazette Pat

1. **Submission Required Under 37 C.F.R. § 1.114**

- a. ☐ Previously submitted
- i. ☐ Consider the amendment(s)/reply under 37 C.F.R. § 1.116 previously filed on \_\_\_\_\_  
(Any unentered amendment(s) referred to above will be entered)
- ii. ☐ Consider the arguments in the Appeal Brief or Reply Brief previously filed on \_\_\_\_\_
- iii. ☐ Other \_\_\_\_\_

- b. ☒ Enclosed
- i. ☒ Amendment/Reply
- ii. ☐ Affidavit(s)/Declaration(s)
- iii. ☐ Information Disclosure Statement (IDS)
- iv. ☒ Other **Petition for Extension of Time**

2. **Miscellaneous**

- a. ☐ Suspension of Action on the above-identified application is requested under 37 C.F.R. § 1.103(c) for a period of \_\_\_\_\_ months (period shall not exceed three months; Fee under 37 C.F.R. § 1.17(i) required)
- b. ☐ Other \_\_\_\_\_

3. **Fees** The RCE fee under 37 C.F.R. § 1.17(e) is required by 37 C.F.R. § 1.114 when the RCE is filed.

- a. ☐ The Director is hereby authorized to charge the following fees, or credit any overpayments, to Deposit Account No. 01-2340
- i. ☐ RCE fee required under 37 C.F.R. § 1.17 (e)
- ii. ☐ Extension of Time Fee (37 C.F.R. §§ 1.136 and 1.17)
- iii. ☐ Other \_\_\_\_\_
- b. ☒ Check in the amount of **\$850.00** is enclosed. \$740.00 filing fee and \$110.00 Extension of Time fee.

RECEIVED

AUG 07 2002

TECH CENTER 1600/2900

08/05/2002 TGEDAMU1 00000060 09718388

740.00 OP

01 FC:179

REQUES OR  
CONTINUED EXAMINATION (RCE)  
TRANSMITTAL

Subsection (b) of 35 U.S.C. § 132, effective on May 29, 2000, provides for the continued examination of a utility or plant application filed on or after June 8, 1995.

PAGE 2



23850

PATENT TRADEMARK OFFICE

Atty Docket No.

001554

SIGNATURE BY APPLICANT, ATTORNEY, OR AGENT REQUIRED

Name Daniel A. Geselowitz, Ph.D.

Registration No. 42,573 (agent)

Signature


Date August 2, 2002

CERTIFICATE OF MAILING OR TRANSMISSION

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to Commissioner for Patents, BOX RCE, Washington, D.C. 20231, or facsimile transmitted to the U.S. Patent and Trademark Office on:

Name

Signature



# 14/D 08  
8/10/02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of: YAMAMOTO, Nobutaka et al.

Group Art Unit: 1636

Serial No.: 09/718,388

Examiner: Konstantina T. Katcheves

Filed: November 24, 2000

P.T.O. Confirmation No.: 3765

FOR: METHOD FOR CULTURING CELL AND A CULTURE VESSEL

AMENDMENT ACCOMPANYING REQUEST FOR CONTINUED EXAMINATION

Commissioner for Patents  
Washington, D.C. 20231

August 2, 2002

Sir:

In response to the Office Action dated April 8, 2002, extended to August 8, 2002, by a one-month Petition for Extension of Time, please amend the application as follow:

CLEAN VERSION OF AMENDMENTS

RECEIVED  
AUG 07 2002  
TECH CENTER 1600/2900

IN THE CLAIMS

1. (Twice Amended) A method for adhering and proliferating target cells, which comprises the steps of:  
inoculating, culturing and then killing in a culture vessel, fibroblasts derived from a mammal, so as to leave an extracellular matrix on a surface of said culture vessel, and then culturing the target cells in said culture vessel.

sub  
E1  
D1